Level Biotechnology (ROCO:3118) Current Deferred Revenue: NT$149.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3118 Level Biotechnology Inc ROCO:3118
73 GF Score
Price NT$31.65
GF Value NT$33.06
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Level Biotechnology Current Deferred Revenue?

Level Biotechnology ROCO:3118 73 Current Deferred Revenue is NT$149.2 Mil as of Jun. 2026. GuruFocus rates ROCO:3118 with a GF Score™ of 73/100 and a GF Value™ of NT$33.06 (Fairly Valued). The stock has 2 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Level Biotechnology's current deferred revenue for the quarter that ended in Jun. 2026 was NT$149.2 Mil.

Level Biotechnology Current Deferred Revenue Related Terms

Level Biotechnology Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Level Biotechnology's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Level Biotechnology Current Deferred Revenue Chart

Level Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 128.11 151.13 154.34 153.23 154.16

Level Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 153.63 139.05 154.16 143.59 149.23
ROCO:3118
73GF Score
Level Biotechnology Inc ROCO:3118
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of NT$149.2 Mil mean?
Level Biotechnology (ROCO:3118) has a Current Deferred Revenue of NT$149.2 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Level Biotechnology and its competitors.
Is Level Biotechnology's Current Deferred Revenue too high?
Level Biotechnology's current Current Deferred Revenue is NT$149.2 Mil. Overall, Level Biotechnology has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Level Biotechnology's Current Deferred Revenue compare to VRTX and REGN?
Level Biotechnology's Current Deferred Revenue of NT$149.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Level Biotechnology and its competitors. Level Biotechnology's current Current Deferred Revenue is NT$149.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Level Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Level Biotechnology (ROCO:3118) is currently considered Fairly Valued. The stock's GF Value™ is NT$33.06, compared to a current price of NT$31.65 — trading 4.3% below its estimated fair value. The current Current Deferred Revenue is NT$149.2 Mil. Level Biotechnology's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Level Biotechnology (ROCO:3118), the current Current Deferred Revenue is NT$149.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Level Biotechnology (ROCO:3118) Overvalued in 2026?

Based on GuruFocus' analysis, Level Biotechnology stock appears to be undervalued. The current stock price of NT$31.65 is trading 4.3% below its estimated GF Value™ of NT$33.06. GuruFocus considers Level Biotechnology to be Fairly Valued.

Key valuation signals for ROCO:3118:

  • Current Deferred Revenue: NT$149.2 Mil
  • GF Value™: NT$33.06 vs. price of NT$31.65 (4.3% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the ROCO:3118 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Level Biotechnology Business Description

Address No. 80, Lane 169, Kangning Street, Xizhi District, New Taipei City, TWN, 221
Level Biotechnology Inc is a Taiwan-based company engaged in the sales of biomedical products and providing preclinical testing services. The company has three reportable segments: Department A and B, Department C, and Department D. Department A and Department B sell the cell culture consumables and the antibody reagents, Department C sells the instruments and equipment, and Department D provides CRO services. The majority of revenue is derived from the Department A and B.
73GF Score

Get the complete analysis for ROCO:3118

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$31.65
Price
NT$33.06
GF Value